Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) signed a letter of intent with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.
As quoted in the press release:
AES Environment has expertise in in situ air testing analysis of all kinds of contaminants and development of high level air cleaners for professional and institutional purposes. They design and manufacture effective filtration devices to answer specific needs of professionals in different areas. In the context of a clinical trial with both on site and at home use of PPP001, it is imperative for Tetra to control the quality of the environment of its users and ensure that caregivers, healthcare professionals (HCP) and family members, will not be affected by second hand smoke when patients are inhaling PPP001 or medical cannabis.
Tetra is being proactive in addressing the concerns of physicians and Health Canada regarding potential effects of second hand smoke. It is for this reason that Tetra is partnering with AES Environment who will provide devices that will allow healthcare professionals to safely work alongside patients smoking prescribed medical cannabis.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).